256 related articles for article (PubMed ID: 27322211)
1. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.
Pozdeyev N; Yoo M; Mackie R; Schweppe RE; Tan AC; Haugen BR
Oncotarget; 2016 Aug; 7(32):51619-51625. PubMed ID: 27322211
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the consistency of large-scale pharmacogenomic studies.
Rahman R; Dhruba SR; Matlock K; De-Niz C; Ghosh S; Pal R
Brief Bioinform; 2019 Sep; 20(5):1734-1753. PubMed ID: 31846027
[TBL] [Abstract][Full Text] [Related]
3. Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer.
Ansari AA; Park I; Kim I; Park S; Ahn SM; Lee JL
BMC Med Genomics; 2018 Oct; 11(1):88. PubMed ID: 30285760
[TBL] [Abstract][Full Text] [Related]
4. IPCT: Integrated Pharmacogenomic Platform of Human Cancer Cell Lines and Tissues.
Shoaib M; Ansari AA; Haq F; Ahn SM
Genes (Basel); 2019 Feb; 10(2):. PubMed ID: 30813377
[No Abstract] [Full Text] [Related]
5. Ensembled machine learning framework for drug sensitivity prediction.
Sharma A; Rani R
IET Syst Biol; 2020 Feb; 14(1):39-46. PubMed ID: 31931480
[TBL] [Abstract][Full Text] [Related]
6. GDSCTools for mining pharmacogenomic interactions in cancer.
Cokelaer T; Chen E; Iorio F; Menden MP; Lightfoot H; Saez-Rodriguez J; Garnett MJ
Bioinformatics; 2018 Apr; 34(7):1226-1228. PubMed ID: 29186349
[TBL] [Abstract][Full Text] [Related]
7. Revisiting inconsistency in large pharmacogenomic studies.
Safikhani Z; Smirnov P; Freeman M; El-Hachem N; She A; Rene Q; Goldenberg A; Birkbak NJ; Hatzis C; Shi L; Beck AH; Aerts HJWL; Quackenbush J; Haibe-Kains B
F1000Res; 2016; 5():2333. PubMed ID: 28928933
[TBL] [Abstract][Full Text] [Related]
8. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
Wang L; Li X; Zhang L; Gao Q
BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
[TBL] [Abstract][Full Text] [Related]
9. PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis.
Feizi N; Nair SK; Smirnov P; Beri G; Eeles C; Esfahani PN; Nakano M; Tkachuk D; Mammoliti A; Gorobets E; Mer AS; Lin E; Yu Y; Martin S; Hafner M; Haibe-Kains B
Nucleic Acids Res; 2022 Jan; 50(D1):D1348-D1357. PubMed ID: 34850112
[TBL] [Abstract][Full Text] [Related]
10. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
Yang W; Soares J; Greninger P; Edelman EJ; Lightfoot H; Forbes S; Bindal N; Beare D; Smith JA; Thompson IR; Ramaswamy S; Futreal PA; Haber DA; Stratton MR; Benes C; McDermott U; Garnett MJ
Nucleic Acids Res; 2013 Jan; 41(Database issue):D955-61. PubMed ID: 23180760
[TBL] [Abstract][Full Text] [Related]
11. Somatic pharmacogenomics in cancer.
Ikediobi ON
Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic agreement between two cancer cell line data sets.
;
Nature; 2015 Dec; 528(7580):84-7. PubMed ID: 26570998
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
Robert J
J Chemother; 2004 Nov; 16 Suppl 4():22-4. PubMed ID: 15688604
[TBL] [Abstract][Full Text] [Related]
14. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
Huang S; Hu P; Lakowski TM
BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
[TBL] [Abstract][Full Text] [Related]
15. Application of transfer learning for cancer drug sensitivity prediction.
Dhruba SR; Rahman R; Matlock K; Ghosh S; Pal R
BMC Bioinformatics; 2018 Dec; 19(Suppl 17):497. PubMed ID: 30591023
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pharmacogenomic agreement.
Safikhani Z; El-Hachem N; Quevedo R; Smirnov P; Goldenberg A; Juul Birkbak N; Mason C; Hatzis C; Shi L; Aerts HJ; Quackenbush J; Haibe-Kains B
F1000Res; 2016; 5():825. PubMed ID: 27408686
[TBL] [Abstract][Full Text] [Related]
17. Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors.
Jang IS; Dienstmann R; Margolin AA; Guinney J
Pac Symp Biocomput; 2015; 20():32-43. PubMed ID: 25592566
[TBL] [Abstract][Full Text] [Related]
18. Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics.
Sarris K; Komianou A; Patrinos GP; Katsila T
Public Health Genomics; 2017; 20(2):142-147. PubMed ID: 28704821
[TBL] [Abstract][Full Text] [Related]
19. Inconsistency in large pharmacogenomic studies.
Haibe-Kains B; El-Hachem N; Birkbak NJ; Jin AC; Beck AH; Aerts HJ; Quackenbush J
Nature; 2013 Dec; 504(7480):389-93. PubMed ID: 24284626
[TBL] [Abstract][Full Text] [Related]
20. AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets.
Hu ZT; Ye Y; Newbury PA; Huang H; Chen B
Pac Symp Biocomput; 2019; 24():248-259. PubMed ID: 30864327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
